Zealand Pharma announced that the FDA has approved Zegalogue (dasiglucagon) injection for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and… read more.
Endocrine-disrupting chemicals may influence hormonal shifts during pregnancy as well as contribute to postpartum depression, according to a small study published in the Endocrine Society’s Journal of Clinical Endocrinology &… read more.
In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass,… read more.
A new once-weekly basal insulin injection demonstrated similar efficacy and safety and a lower rate of low blood sugar episodes compared with a daily basal insulin, according to… read more.
Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, announced positive results from the first pivotal trial… read more.
Research from Queen Mary University of London has concluded that there is convincing evidence that type 2 diabetes is associated with an increased risk of Parkinson’s disease. The… read more.
Article by Bruce Sylvesyter. In tandem with lifestyle management, once-weekly semaglutide therapy has enabled obese, non-diabetic patients to lose a significant amount of weight, researchers reported on Feb…. read more.
Interview and article written by Christine Clark With advancing age many people now look forward to a future in which digital solutions will support effective self-management and independent… read more.
New research from the University of Sheffield has found being overweight is an additional burden on brain health and it may exacerbate Alzheimer’s disease.
Heart disease remains the leading cause of death worldwide, according to the American Heart Association’s Heart Disease and Stroke Statistics — 2021 Update,
Article written by Bruce Sylvester Women under 55 with type-2 diabetes have a 10-fold increased risk of developing coronary heart disease (CHD) during the two decades following diagnosis,… read more.
A Duke-led team of scientists has developed a bio-compatible surgical patch that releases non-opioid painkillers directly to the site of a wound for days and then dissolves away.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
